Back to Market返回行情

GRFS Grifols, S.A.

USHealthcare
$7.27-0.27%ClosedMarket Cap: $6.15B

As of 2026-07-10 16:00

Why GRFS matters now

Grifols, S.A. (GRFS) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.27 with -0.27% on the session and $6.15B in market capitalization; recent performance reads 1-month -5.61% and YTD -20.86%.

The latest financial table shown here is Q1 2026, with revenue of $1.73B, net income of $74.2M, and EPS of $0.11. Investors can compare that operating picture with valuation signals such as P/E 17.32 and FCF yield 12.2%.

The latest indexable market news headline is "Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)" from Seeking Alpha.

Additional event context on this page matters because analyst consensus is Hold with a median target of $—. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

17.32

PEG

0.11

P/B

1.14

P/S

0.83

EV/EBITDA

10.58

DCF Value

$22.42

FCF Yield

12.2%

Div Yield

1.6%

Margins & Returns

Gross Margin

37.7%

Operating Margin

16.9%

Net Margin

5.6%

ROE

7.9%

ROA

2.1%

ROIC

5.5%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$1.73B$74.2M$0.11
Q4 2025$1.96B$97.3M$0.14
FY 2025$7.23B$386.1M$0.57
Q3 2025$1.87B$127.0M$0.19

Analyst Ratings

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 0Buy: 1Hold: 1Sell: 0Strong Sell: 0
JP MorganNeutral
2025-12-08

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

ES

Exchange

Beta

1.17

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.